Similarly, in the colon cancer model (CT26), toxicities observed in the SLC-CTLA4 group were less compared to the group with systemic CTLA-4 blockade (increase in body weight by ~30% compared to ~10%) [126]. Here, CTLA4 is linked to malignant colon neoplasm.